
Managing High-Risk NMIBC
The treatment landscape for high-risk non-muscle-invasive bladder cancer (NMIBC) is rapidly evolving. This resource aims to equip you with the information you need to select the right treatment options for your patients, with focused overviews of diagnostic and treatment pathways, plus the latest from ASCO GU, EAU, AUA, and ASCO.
And keep an eye out for our NMIBC podcast series, with a focus on tackling clinical challenges in providing optimal care, launching soon.
ASCO 2025: Expert interviews
Hear from Thomas Powles and Gary Steinberg about recent trial data presented at ASCO 2025 and the potential impact for NMIBC management.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event